Compare Medpace Holdings Inc (MEDP) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Toronto-Dominion Bank — how do they compare? Medpace Holdings Inc trades at $618.43 (market cap $16.82B), while Toronto-Dominion Bank trades at $114.43 (market cap $185.79B). The key difference: Toronto-Dominion Bank is far larger — about 11× Medpace Holdings Inc's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Toronto-Dominion Bank for 84 Days on average.
| MEDP | TD | |
|---|---|---|
Market Cap | $16.82B | $185.79B |
Volume | 223,093 | 3,263,867 |
Sector | Health | Financials |
52-Week High | $630.19 | $124.80 |
52-Week Low | $393.42 | $78.32 |
Typical Hold Time | 14 Days | 84 Days |
Enterprise Value | $16.44B | $559.06B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
TD Bank trades at $114.39, up 0.46% with bearish technical signals despite strong earnings beats. The stock shows robust fundamentals with 24.88% net margin and 13.64% ROE, supported by a $10 billion buyback program announced September 2026. Revenue growth accelerated to $61.28 billion in 2025 with profit margins recovering to 33.51%. Analyst consensus leans bullish with 9 buy ratings versus 8 holds and no sell recommendations.
TD presents a compelling value opportunity with reasonable P/E of 17.36 and consistent earnings outperformance. Key risks include declining operating cash flow trends and elevated debt-to-asset ratio of 20.86%. The bank's $108 billion Canadian infrastructure commitment and U.S. branch expansion provide growth catalysts, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
